| scholarly article | Q13442814 |
| P50 | author | Bruno Pereira | Q38523070 |
| Nassim Kamar | Q49264830 | ||
| Martin Soubrier | Q58884902 | ||
| P2093 | author name string | Eric Thervet | |
| Dany Anglicheau | |||
| Anthony Buisson | |||
| Philippe Gatault | |||
| Sophie Caillard | |||
| Nicolas Bouvier | |||
| Cyril Garrouste | |||
| Charlotte Colosio | |||
| Johnny Sayegh | |||
| Joseph Rivalan | |||
| Julien Aniort | |||
| Anne Elisabeth Heng | |||
| Claire Bachelier | |||
| P2860 | cites work | Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis | Q27011853 |
| Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials | Q33243658 | ||
| Tumor necrosis factor-alpha inhibitor-induced lupus-like syndrome presenting as fever of unknown origin in a liver transplant recipient: case report and concise review of the literature | Q33380140 | ||
| Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease | Q33786255 | ||
| Anti-TNF-alpha therapies: the next generation | Q34227176 | ||
| Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis | Q34498486 | ||
| Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis | Q34556944 | ||
| Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety | Q35044577 | ||
| Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort | Q35750365 | ||
| Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab | Q35852535 | ||
| Infection in solid-organ transplant recipients | Q37038203 | ||
| Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster | Q37171211 | ||
| Anti-TNF-induced lupus | Q37471071 | ||
| The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study | Q37806620 | ||
| Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis | Q37854256 | ||
| TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists | Q37867162 | ||
| Kidney transplantation in the older adult. | Q38069319 | ||
| Malignancies: pre and post transplantation strategies. | Q38179658 | ||
| Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. | Q38180195 | ||
| TNF receptors: signaling pathways and contribution to renal dysfunction | Q38241605 | ||
| Safety of anti-tumor necrosis factor therapies in arthritis patients. | Q38249916 | ||
| Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk | Q38344101 | ||
| Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease | Q38450732 | ||
| Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis | Q38585383 | ||
| Use of etanercept for psoriasis in a liver transplant recipient | Q39564856 | ||
| Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers | Q39793022 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer | Q40383687 | ||
| Previous Cancer/Lymphoma and Refractory Inflammatory Bowel Disease | Q40542226 | ||
| Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents | Q40655110 | ||
| Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. | Q40711840 | ||
| Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). | Q42439252 | ||
| Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease | Q42490631 | ||
| The effect of immunosuppression on pre-existing cancers | Q42511271 | ||
| The use of the tumour necrosis factor antagonist infliximab in heart transplant recipients: two case reports | Q42753877 | ||
| Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study | Q43259606 | ||
| Mycobacterial diseases and antitumour necrosis factor therapy in USA. | Q43907152 | ||
| Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden | Q46651326 | ||
| Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study | Q46688627 | ||
| The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. | Q46782341 | ||
| Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation | Q46929838 | ||
| Etanercept therapy for severe plaque psoriasis in a patient who underwent a liver transplant. | Q46935796 | ||
| Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. | Q51326369 | ||
| Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. | Q51736656 | ||
| [Granulomatous interstitial nephritis in a patient with Behçet's disease treated with infliximab]. | Q54297613 | ||
| Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry | Q56838445 | ||
| Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience | Q57948785 | ||
| Drug-induced systemic lupus erythematosus associated with etanercept therapy | Q77696979 | ||
| Infliximab for ulcerative colitis following liver transplantation | Q79777123 | ||
| Infliximab as therapeutic option in steroid-refractory ulcerative colitis after kidney transplantation: case report | Q82540859 | ||
| Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant | Q82900635 | ||
| Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation | Q84164186 | ||
| The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series | Q84194593 | ||
| Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient | Q85417816 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e5108 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Anti-TNFα therapy for chronic inflammatory disease in kidney transplant recipients: Clinical outcomes | |
| P478 | volume | 95 |
Search more.